Admescope acquires MetaSafe to build European ADME-focused CRO

0
6


Admescope has acquired Swedish contract research organization MetaSafe AB, which focuses on metabolic research and drug biotransformation. Financial terms were not disclosed.

Oulu, Finland-based Admescope, which offers services in toxicology and pharmacokinetics, said it hopes the purchase will strengthen its drug metabolism services in clinical-phase projects, and that it will also provide access to MetaSafe’s laboratory facility.

“We are excited about the acquisition, and warmly welcoming MetaSafe’s experienced experts as a part of the Admescope team,” Admescope CEO Ari Tolonen said in a statement. “Due to the excellent synergy between the companies’ service portfolios and operative models, this acquisition will add value for both MetaSafe’s and Admescope’s customers, as together we create a more comprehensive service offering with strengths from the both companies.”

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

The merger aims to create a unique ADME-focused CRO, providing both preclinical and clinical services to support lead candidate optimization.

“MetaSafe’s and Admescope’s services are highly complementary, and in the future we will be in a position to provide our customers with a comprehensive offering from a single source for everything relating to ADME services in order to ensure early and late lead candidate optimization,” said Johanna Haglund, CEO of MetaSafe.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here